Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice

As a long-acting formulation of the nonnucleoside reverse transcriptase inhibitor rilpivirine (RPV LA) has been proposed for use as preexposure prophylaxis (PrEP) and the prevalence of transmitted RPV-resistant viruses can be relatively high, we evaluated the efficacy of RPV LA to inhibit vaginal tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Melody, Kevin, Roy, Chandra N., Kline, Christopher, Cottrell, Mackenzie L., Evans, Dwayne, Shutt, Kathleen, Pennings, Pleuni S., Keele, Brandon F., Bility, Moses, Kashuba, Angela D. M., Ambrose, Zandrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Vaccines and Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108851/
https://www.ncbi.nlm.nih.gov/pubmed/31969438
http://dx.doi.org/10.1128/JVI.01912-19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7108851/
https://www.ncbi.nlm.nih.gov/pubmed/31969438
http://dx.doi.org/10.1128/JVI.01912-19

Ejemplares similares